ijms-logo

Journal Browser

Journal Browser

The Role of Nutraceuticals in Gastrointestinal Diseases and the Applications in Microbiota

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Bioactives and Nutraceuticals".

Deadline for manuscript submissions: closed (15 April 2024) | Viewed by 937

Special Issue Editor


E-Mail Website
Guest Editor
Department of Biomolecular Sciences, University of Urbino Carlo Bo, 61122 Urbino, Italy
Interests: microbiota; nutraceuticals; probiotics; prebiotics; postbiotics; botanicals; IBS; IBD; GERD

Special Issue Information

Dear colleagues,

Nutraceuticals represent a reality that is progressively finding a concrete role in clinical practice in a technical-regulatory scenario that remains controversial in some respects. The placement of food substances with pharmaceutical effects places them in an intermediate condition between that of food and that of active ingredients. This complex scenario is further complicated by the emerging knowledge relating to the microbiota, which open new scenarios regarding the prebiotic potential (and the related postbiotics that could derive from it) for nutraceutical substances. Gastrointestinal diseases, in their direct effects and in their metabolic applications, in this context, represent one of the first and main scenarios where the effect of nutraceuticals can and must be investigated, starting from the compositional aspects, analyzing the known biological‒molecular effects, reaching to proven or potential clinical applications. In particular, the study of synergistic applications to the conventionally used pharmacological ones also represents a further element aimed at the development of new possible therapeutic potentials.

Therefore, this Special Issue entitled "The Role of Nutraceuticals in Gastrointestinal Diseases and the Applications in Microbiota" will discuss the recent advances in the molecular metabolic mechanisms highlighted for nutraceutical substances used in the management of Gastrointestinal Disorders, analyzing both the direct effects of and the implications due to the interaction with the microbiota.

Arguments relating to both original and reviewed articles are welcome.

Dr. Alexander Bertuccioli
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • microbiota
  • nutraceuticals
  • probiotics
  • prebiotics
  • postbiotics
  • IBS
  • IBD
  • GERD

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Other

15 pages, 2000 KiB  
Hypothesis
The Potential Role of Probiotics, Especially Butyrate Producers, in the Management of Gastrointestinal Mucositis Induced by Oncologic Chemo-Radiotherapy
by Massimiliano Cazzaniga, Marco Cardinali, Francesco Di Pierro, Giordano Bruno Zonzini, Chiara Maria Palazzi, Aurora Gregoretti, Nicola Zerbinati, Luigina Guasti and Alexander Bertuccioli
Int. J. Mol. Sci. 2024, 25(4), 2306; https://doi.org/10.3390/ijms25042306 - 15 Feb 2024
Viewed by 721
Abstract
Many clinical studies have now highlighted how the composition of the intestinal microbiota can regulate the effects of many oncological therapies. In particular, the modulation of microbial composition has been shown to enhance their efficacy and reduce potential side effects. Numerous adverse events [...] Read more.
Many clinical studies have now highlighted how the composition of the intestinal microbiota can regulate the effects of many oncological therapies. In particular, the modulation of microbial composition has been shown to enhance their efficacy and reduce potential side effects. Numerous adverse events induced by chemotherapy and radiotherapy appear to be strongly associated with an alteration in the intestinal microbiota caused by these treatments. This supports the hypothesis that the modulation or correction of the microbiota may decrease the toxic impact of therapies, improving patient compliance and quality of life. Among the most debilitating disorders related to oncological treatments is certainly mucositis, and recent clinical data highlight how the deficiency of short-chain fatty acids, especially butyrate, and specifically the lack of certain bacterial groups responsible for its production (butyrate producers), is strongly associated with this disorder. It is hypothesized that restoring these elements may influence the onset and severity of adverse events. Therefore, the intake of probiotics, especially butyrate producers, and specifically Clostridium butyricum (CBM588), currently the only cultivable and usable strain with a history of data proving its safety, could be a valuable ally in oncological therapies, reducing the associated discomfort and improving compliance, efficacy, and quality of life for patients. Full article
Show Figures

Figure 1

Back to TopTop